TY - JOUR
T1 - Concomitant use of alcohol and benzodiazepine hypnotics in psychiatric outpatients
T2 - A cross-sectional survey
AU - Uchida, Takahito
AU - Hirano, Jinichi
AU - Sakurai, Hitoshi
AU - Suzuki, Takefumi
AU - Mimura, Masaru
AU - Uchida, Hiroyuki
N1 - Funding Information:
T.U. has received research grants from Novartis and Inogashira Hospital (Tokyo, Japan); speaker’s honoraria from Dainippon-Sumitomo, Mochida Pharmaceutical, Yoshitomi Pharmaceutical, and Meiji Pharmaceutical within the past 3 years. J.H. has received grants from Pfizer Health Research Foundation within the past 3 years. H.S. has received manuscript or speaker’s honoraria from Dainippon-Sumitomo, Eli Lilly, Meiji-Seika Pharma, Otsuka Pharmaceutical, Tanabe Mitsubishi Pharma, and Yoshitomi Yakuhin within the past 3 years. T.S. has received manuscript or speaker’s fees from Astellas, Dainippon Sumitomo Pharma, Eli Lilly, Elsevier Japan, Janssen Pharmaceuticals, Meiji Seika Pharma, Novartis, Otsuka Pharmaceutical, Wiley Japan, and Yoshitomi Yakuhin, and research grants from Eisai, Mochida Pharmaceutical, and Meiji Seika Pharma. M.M. has received grants and speaker’s honoraria from Asahi Kasei Pharma, Astellas Pharmaceutical, Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, Fuji Film Pharma, Japan Chemiphar, Janssen Pharmaceutical, Kracie, Maruho, Meiji-Seika Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Shionogi, SRL, Takeda, Tanabe Mitsubishi Pharma, and Yoshitomi Yakuhin within the past 3 years. H.U. has received grants from Eisai, Otsuka Pharmaceutical, Dainippon-Sumitomo Pharma, Mochida Pharmaceutical, Meiji-Seika Pharmaceutical, and Novartis; speaker’s honoraria from Otsuka Pharmaceutical, Eli Lilly, Shionogi, Pfizer, Yoshitomi Yakuhin, Dainippon-Sumitomo Pharma, Meiji-Seika Pharma, MSD, and Janssen Pharmaceutical; and advisory panel payments from Dainippon-Sumitomo Pharma within the past 3 years.
Publisher Copyright:
© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Concomitant use of benzodiazepines and alcohol appears prevalent in a clinical setting. The objectives of this study were as follows: (1) to investigate the prevalence of concomitant use of benzodiazepine hypnotics and alcohol in psychiatric outpatients, (2) to examine the clinical characteristics and factors associated with the concomitant use, and (3) to investigate the awareness of the psychiatrists-in-charge about the concomitant use. Outpatients with schizophrenia, depression, and insomnia who were receiving benzodiazepine hypnotics were asked to fill in a sleeping diary for seven consecutive days in which use of hypnotics and alcohol was also recorded. Clinical characteristics were assessed, and logistic analysis was performed to examine factors associated with the concomitant use. In addition, psychiatrists-in-charge were asked as to whether they thought their patients were concomitantly using them. The prevalence rate of the concomitant use was 39.8% (37/93). The CAGE score showed significant positive association with the concomitant use (odds ratio = 2.40, 95% confidence interval = 1.39-4.16, P = 0.002). Only in 32.4% of the concomitant users were suspected by their psychiatrists. The results suggest that concomitantly used benzodiazepine hypnotics and alcohol appears prevalent, and has been frequently overlooked by treating psychiatrists. The CAGE questionnaire may be helpful to screen such potentially hazardous users.
AB - Concomitant use of benzodiazepines and alcohol appears prevalent in a clinical setting. The objectives of this study were as follows: (1) to investigate the prevalence of concomitant use of benzodiazepine hypnotics and alcohol in psychiatric outpatients, (2) to examine the clinical characteristics and factors associated with the concomitant use, and (3) to investigate the awareness of the psychiatrists-in-charge about the concomitant use. Outpatients with schizophrenia, depression, and insomnia who were receiving benzodiazepine hypnotics were asked to fill in a sleeping diary for seven consecutive days in which use of hypnotics and alcohol was also recorded. Clinical characteristics were assessed, and logistic analysis was performed to examine factors associated with the concomitant use. In addition, psychiatrists-in-charge were asked as to whether they thought their patients were concomitantly using them. The prevalence rate of the concomitant use was 39.8% (37/93). The CAGE score showed significant positive association with the concomitant use (odds ratio = 2.40, 95% confidence interval = 1.39-4.16, P = 0.002). Only in 32.4% of the concomitant users were suspected by their psychiatrists. The results suggest that concomitantly used benzodiazepine hypnotics and alcohol appears prevalent, and has been frequently overlooked by treating psychiatrists. The CAGE questionnaire may be helpful to screen such potentially hazardous users.
KW - alcohol
KW - benzodiazepine
KW - depression
KW - insomnia
KW - schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85072746587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072746587&partnerID=8YFLogxK
U2 - 10.1097/YIC.0000000000000264
DO - 10.1097/YIC.0000000000000264
M3 - Article
C2 - 30998597
AN - SCOPUS:85072746587
SN - 0268-1315
VL - 34
SP - 291
EP - 297
JO - International clinical psychopharmacology
JF - International clinical psychopharmacology
IS - 6
ER -